About us
An independent French company, Laboratoires Brothier specializes in the development of biopolymers extracted from brown algae, intended for hemostasis and tissue repair.
A global pioneer in the use of calcium alginates, BROTHIER developed the first industrial processes in the mid-20th century to produce these marine-based biopolymers (brown seaweed) in textile form.
The resulting high-tech compresses, dressings, patches, and powders are used in numerous medical applications, from treating nosebleeds to managing complex surgical wounds.
Over time, Brothier has established fundamental research partnerships with public, private, and military centres, including Research institutes with an international reach (CNRS, INSERM), and the Biomedical Research Institute of the French Armed Forces. The findings from these research efforts allow Brothier to design the therapies of tomorrow.
Our history
1949
Creation of Brothier and launch of Colagan
1962
Reimbursement of Coalgan by French Social Security system
1980
Stop Hemo launch
1991
Launch of Algosteril
1996
1st Prize in Clinical Methodology SAWC Atlanta, USA
2011
FDA approval for Algosteril
2013
ISO 14001 Environment Certification
2015
Extension of the production site
2017
1st prize for innovation from the French Society of Plastic and Reconstructive Surgery
2019
Brothier celebrates its 70th anniversary
2021
Algosteril vs NWPT at the World Congress of Surgery (SF, USA)
2024
Brothier celebrates its 75th anniversary at the Château de Saumur !
2025
Start of new extension works at the factory (Fontevraud-l’Abbaye)
Remaining French and independent is our credo for preserving our freedom of action and long-term vision. In a globalised world, our industrial and scientific programs prioritise the national territory while also being active in international markets.
President, Laboratoires Brothier
Brothier at a glance:
150
employees
20
to which Brothier products are exported
100%
of our seaweed-based medical devices are designed and manufactured in France
90/ 100
on the Gender Equality Index (2023)
52
in turnover (2023)
14%
of turnover dedicated to R&D.